Zydus Lifesciences has added one other regulatory milestone to its report, securing a clear USFDA report for its Ahmedabad SEZ-II facility. The event comes simply days earlier than the corporate’s board meets to think about a Rs 5,000 crore fundraising plan.
The USFDA issued an Institution Inspection Report (EIR) classifying the positioning as “No Motion Indicated” (NAI). This adopted a Pre-Approval Inspection (PAI) carried out between eleventh and 14th August, 2025. The inspection concluded with no observations, reaffirming the corporate’s robust compliance requirements.
The optimistic consequence strengthens Zydus’ place because it prepares for its sixth November board assembly. In the course of the assembly, they may talk about elevating funds via choices akin to a QIP, rights subject, or personal placement. Moreover, a postal poll course of can even be initiated to hunt shareholder approval.
Zydus will announce its July–September quarter outcomes the identical day. In Q1 FY26, it reported a 3.3% rise in web revenue to Rs 1,467 crore. Income was up 6% year-over-year to Rs 6,574 crore, at the same time as EBITDA margins narrowed barely to 31.8%.
Prepared to take a position like a professional? Unicorn Indicators app equips you with 100+ Free instruments and information it is advisable to succeed. Obtain the Unicorn Indicators app and achieve entry to every day inventory lists and insightful market evaluation and way more!
